TAKEUCHI Tsutomu

タケウチツトム | TAKEUCHI Tsutomu

Affiliation and department：
Job title： Other

Research field (1)： Allergies and connective tissue disease

Research keywords (3)： Rheumatoid Arthritis , 自己免疫疾患 , 生物学的製剤

Research theme for competitive and other funds (20)：

2017 - 2020 自己免疫疾患における病変局所の自己反応性免疫細胞の網羅的解析
2014 - 2017 Investigation of regulatory mechanism of secretary protein kinase and its application for treatment of rheumatoid arthritis
2008 - 2010 CD103分子を介した多様な機能発現に関与するシグナル伝達経路の解析
2006 - 2009 末梢血によるRA早期疾患シグニチャー解析法の開発と確立
2008 - 関節リウマチ患者の生命予後からみた至適医療の確立に関する臨床研究

Show all

Papers (734)：

Tanaka Y, Takeuchi T, Morita Y, Kaneko Y, and Terada W. Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2). Modern Rheumatology. 2023
Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coobms D, Liu J, Anyanwu SI, Lippe R, and Curtis JR. Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Rheumatology and Therapy. 2023
Feldmann M, Maini RN, Soriano ER, Strand V, and Takeuchi T. 25 years of biologic DMARDs in rheumatology. Nature Review Rheumatology. 2023. 19. 761-766
Takeuchi T, Chino Y, Mano Y, Kawanishi M, Sato Y, Uchida S, and Tanaka Y. Population Pharmacokinetics of ozoralizumab in patients with rheumatoid arthritis. Journal of Clinical Pharmacology. 2023
Takeuchi T, Nakanishi M, Kawanishi M, Yamasaki H, and Tanaka Y. Effect of extended dosing interval of anti-TNF-alpha NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Modern Rheumatology. 2023

ｍore...

MISC (22)：

ｍore...

Books (28)：

ｍore...

Lectures and oral presentations (18)：

関節リウマチの寛解導入療法体系化に関する研究
(平成19年度厚生労働科学研究費補助金免疫アレルギー予防・治療研究事業研究報告会 2008)
SLE難治性病態に対する新規治療法の臨床開発・評価に関する研究-タクロリムスのSLE T細胞機能異常に対する作用および、臨床的有用性の検証-
(平成19年度厚生労働科学研究費補助金難治性疾患克服研究事業自己免疫に関する調査研究班班会議 2008)
関節リウマチの最新治療とは?
(平成18年度厚生労働省免疫アレルギー疾患予防・治療研究事業リウマチシンポジウム 2007)
Safety of Re-infusion of Infliximab in RA Patients: Results from the Post-Marketing Surveillance (PMS) in Japan
(ACR/ARHP Annual Scientific Meeting 2007 2007)
Morphological Alteration and Proliferation of Synovial Fibroblast-like Cells in 3-Dimensional Culture are Induced by Platelet-derived Growth Factor and Inhibited by Imatinib Mesylate
(ACR/ARHP Annual Scientific Meeting 2007 2007)

ｍore...

Awards (3)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page